Management of Respiratory Distress Syndrome: An Update: Ricardo J Rodriguez MD
Management of Respiratory Distress Syndrome: An Update: Ricardo J Rodriguez MD
Management of Respiratory Distress Syndrome: An Update: Ricardo J Rodriguez MD
Ricardo J Rodriguez MD
Introduction Composition and Metabolism of Surfactant Surfactant Replacement for Respiratory Distress Syndrome Ventilatory Management Nitric Oxide for Premature Babies with Respiratory Distress Syndrome Summary
Respiratory distress syndrome is the most common respiratory disorder in preterm infants. Over the last decade, because of improvements in neonatal care and increased use of antenatal steroids and surfactant replacement therapy, mortality from respiratory distress syndrome has dropped substantially. However, respiratory morbidity, primarily bronchopulmonary dysplasia, remains unacceptably high. The management of respiratory distress syndrome in preterm infants is based on various modalities of respiratory support and the application of fundamental principles of neonatal care. To obtain best results, a multidisciplinary approach is crucial. This review discusses surfactant replacement therapy and some of the current strategies in ventilatory management of preterm infants with respiratory distress syndrome. Key words: pediatric, respiratory, pulmonary, respiratory distress syndrome, RDS, surfactant replacement therapy, preterm newborn, bronchopulmonary dysplasia. [Respir Care 2003;48(3):279 286. 2003 Daedalus Enterprises]
Introduction Respiratory distress syndrome (RDS) is the most common respiratory disorder of premature infants. Since the initial description of the association of RDS with surfactant deficiency more than 30 years ago, enormous strides have been made in understanding the pathophysiology and treatment of this disorder.1 The introduction of antenatal steroids for acceleration of lung maturity and the development of exogenous surfactant can be credited with the
Ricardo J Rodriguez MD is affiliated with the Department of Pediatrics, Division of Neonatology, Case Western Reserve University, and Rainbow Babies and Childrens Hospital, Cleveland, Ohio. Ricardo J Rodriguez MD presented a version of this report at the 31st RESPIRATORY CARE Journal Conference, Current Trends in Neonatal and Pediatric Respiratory Care, August 1618, 2002, in Keystone, Colorado. Correspondence: Ricardo J Rodriguez MD, Department of Pediatrics, Division of Neonatology, Rainbow Babies and Childrens Hospital, 11100 Euclid Avenue, Cleveland OH 44106. E-mail: rjr8@po.cwru.edu.
dramatic improvement in the outcome of patients affected with RDS.2 6 Typically, RDS affects preterm infants below 35 weeks of gestational age; however, older infants with delayed lung maturation of different etiologies can also be afflicted. Common risk factors associated with RDS include low gestational age, perinatal asphyxia, and maternal diabetes.7 Hack et al have reported that 56% of infants between 501 and 1,500 g were noted to have RDS and/or respiratory insufficiency of prematurity, including 86% between 501 and 750 g; 79% between 751 and 1,000 g; 48% between 1,001 and 1,250 g; and 27% between 1,251 and 1,500 g.8 RDS presents at birth, or shortly thereafter, with grunting respiration, chest wall retractions, nasal flaring, and increased work of breathing. These patients usually show progression of symptoms and require supplemental oxygen. Hypoxemia and hypercarbia, accompanied by various degrees of respiratory and metabolic acidosis, are the typical findings from arterial blood gas analysis. The pathognomonic radiology findings are bilateral, homogeneous, ground-glass appearance of the lung fields, with hypoin-
279
MANAGEMENT
OF
flation and superimposed air bronchogram. In more severely affected babies, a complete white-out of the lung fields is often observed. The pathophysiology of this disorder has been clearly elucidated. Briefly, the structurally immature and surfactant-deficient lung has a tendency to collapse. The presence of relatively well perfused but poorly ventilated areas of the lung results in ventilation/perfusion mismatch, with hypoxemia and hypercarbia. In some patients, pulmonary vasoconstriction leads to persistence of pulmonary hypertension and right-to-left shunts (via the patent ductus arteriosus and/or the foramen ovale), resulting in more severe hypoxemia. This phenomenon, once thought to be patrimony of the full term infant, is frequently observed in preterm babies with RDS and has led some clinicians to consider the use of inhaled nitric oxide in preterm infants when hypoxemia is unresponsive to adequate support with mechanical ventilation. Fortunately, the natural course of the disease in many low-birthweight infants has been altered by the introduction of exogenous surfactant. The management of these infants is complex and requires a multidisciplinary team approach to obtain best outcomes. The application of the basic principles of neonatal care, such as thermoregulation, cardiovascular and nutritional support, treatment of early neonatal infection, and prevention of nosocomial infection, is crucial to achieve the therapeutic goals. Clearly, surfactant replacement therapy, continuous positive airway pressure (CPAP), and mechanical ventilation in its different modalities are the mainstay for the respiratory support of these patients. Composition and Metabolism of Surfactant In the early 1950s, Clements, Pattle, and others described the presence of a thin layer of material on the alveolar surface of the lungs, which is capable of reducing surface tension to a low level upon dynamic compression.9,10 These were the initial descriptions of the physiologic properties and the role of endogenous pulmonary surfactant in the maintenance of alveolar stability. Surfactant is a complex mixture of phospholipids and proteins and is present in the lungs of all mammalian species. Surfactant obtained from alveolar wash contains 80% phospholipids, (phosphatidylcholine, phosphatidylglycerol, phophatidylinositol, and phophatidylethanolamine), 10% protein (surfactant protein [SP] SP-A, SP-B, SP-C, SP-D and other proteins), and 10% neutral lipids, mainly cholesterol. Phosphatidylcholine, represents 60% of surfactant by weight and accounts for 80% of the phospholipids. Furthermore, saturated phosphatidylcholine is the principal surface-active material in surfactant.11,12 The synthesis of endogenous surfactant is carried out by type II pneumonocytes. The synthetic pathways and enzymes involved in the synthesis of each phospholid have
280
MANAGEMENT
OF
plantation has been used in a handful of patients and is currently the only therapeutic option. Recently, an association of SP-C gene mutation and familial interstitial lung disease has been reported. It is unclear whether SP-C-based surfactant replacement will be efficacious for these patients. The role of surfactant proteins during the acute and the recovery phase of various respiratory disorders in the newborn period is still under intensive investigation. Surfactant Replacement for Respiratory Distress Syndrome Over the last 2 decades, our understanding of the use of surfactant for the treatment of RDS has increased substantially. The administration of exogenous surfactant for the treatment of RDS in preterm infants is probably the most thoroughly evaluated therapy currently used in neonatal intensive care units. Avery and Meads seminal report on the role of surfactant deficiency in the pathophysiology of RDS, then referred to as hyaline membrane disease, brought the facts from bench to bedside.1 Since then, great strides have been made in understanding the pulmonary surfactant system. Fujiwara et al, in Japan, pioneered the introduction of surfactant replacement for the treatment of RDS. In a small, uncontrolled trial, 10 mechanically ventilated infants with clinical and radiologic diagnoses of severe RDS were successfully treated with a modified bovine surfactant extract (Surfactant-TA, Surfacten, Tokyo Tanabe, Tokyo, Japan) administered via endotracheal tube. All infants demonstrated remarkable improvement in oxygenation and decreased ventilatory requirements.2 Numerous multicenter, randomized, controlled studies have since evaluated and confirmed the efficacy and safety of various surfactant preparations, both natural and synthetic, for the treatment of RDS.2226 It is widely accepted that surfactant improves oxygenation, decreases air leaks, and, most importantly, reduces infant mortality from RDS by 40%.22,23,2729 Meta-analysis of clinical trials in which synthetic or natural surfactant was used, either as a prophylactic or rescue treatment, clearly supports these findings.11 Furthermore, it has been estimated that 80% of the decline in infant mortality rate between 1988 and 1990 can be attributed solely to the introduction of surfactant therapy, and this has substantially decreased the cost of care for both surviving and nonsurviving infants.29 Two main classes of surfactant preparations were used during the initial evaluation of surfactant therapy: natural and synthetic.2,22,23,26,30 Both natural and synthetic surfactant preparations seemed effective; however, natural surfactants show a more immediate response in oxygenation and lung compliance.3133 Furthermore, in a meta-analysis by Halliday, the use of natural surfactant was associated with lower mortality, fewer air leaks, and a lower oxygen
281
MANAGEMENT
OF
with RDS from surfactant deficiency responds favorably to this treatment. The need for high oxygen concentration, and high ventilatory pressure during the early stages of RDS have been identified as risk factors for an inadequate response.40,41 Whether the lack of response to surfactant is secondary to the initial severity of the disease or to the damage induced by short periods of aggressive ventilation prior to or after surfactant replacement is not clear. In contrast to the remarkable effects of surfactant therapy on RDS, the incidence of other morbidities, including intraventricular hemorrhage (IVH), sepsis, patent ductus arteriosus, and BPD, has not been substantially altered by surfactant therapy.11,34 The lack of a more marked effect of surfactant replacement on BPD is not too surprising, since the etiology of BPD is multifactorial and cannot be attributed solely to surfactant deficiency. BPD has been traditionally defined as the need for supplemental oxygen at 28 days of life, with chronic radiologic changes. More recently, the need for supplemental oxygen at 36 weeks corrected postconceptional age has been used as a diagnostic criterion. Although the deleterious effects of barotrauma/volutrauma and oxygen toxicity on the surfactant-deficient lung are paramount in the pathogenesis of BPD, a number of prenatal and postnatal factors have also been implicated (low gestational age, low birthweight, male sex, white ethnicity, patent ductus arteriosus, and prenatal and postnatal infection). Furthermore, many preterm infants develop BPD without antecedent RDS.7 The developmental immaturity of the protective antioxidant systems, such as superoxide dismutase, catalase, and vitamin E, may make the verylow-birthweight infant particularly susceptible to oxygen toxicity. Although individual studies have shown a decreased incidence of BPD, these results have not been substantiated by meta-analysis of large, randomized trials.11,34 When different weight categories are analyzed, in the larger infants (birthweight 1,250 g) in whom BPD may be more directly associated with surfactant deficiency and the effects of volutrauma/barotrauma, a trend toward a lower incidence of BPD emerges.42 With more immature infants surviving, a significant increase in BPD might be expected. However, the introduction of surfactant has significantly decreased mortality from RDS, without a substantial increase in BPD rate. Data from clinical trials suggest that more infants are surviving both with and without BPD. Ventilatory Management The goals of ventilatory management during the early stages of RDS are to maintain adequate oxygenation and ventilation, while minimizing ventilator-induced lung injury. The surfactant-deficient lung of the immature infant characteristically has decreased lung compliance, increased
282
MANAGEMENT
OF
mandatory ventilation and demonstrated a modest benefit in pulmonary outcomes. Babies allocated to the HFOV group were extubated at an earlier age (13 vs 21 d), and there was a small but significant increase in survival without supplemental oxygen at 36 weeks corrected age. The United Kingdom trial, in which 3 different high-frequency oscillation ventilators were used, showed no significant differences in the incidence of BPD, death, or other complications. It is important to recognize the substantial center-to-center variability of experience with this ventilation modality, which probably accounts for the differences in reported outcomes.51 Furthermore, the question of whether high-frequency ventilation should be used as a primary mode of ventilation or a rescue modality remains unresolved, mainly because of serious concerns regarding central nervous system complications.50 In recent years, permissive hypercapnia, a strategy intended to minimize ventilator-induced lung injury, has gained popularity. Briefly, in this approach, the patients arterial carbon dioxide concentration is kept between 45 and 55 mm Hg. In animal models the use of permissive hypercapnia was associated with less lung injury.57 Furthermore, clinical studies in adults with acute respiratory distress syndrome have shown increased survival. Theoretically, the potential advantages from this approach include less volutrauma, fewer adverse effects from hypocapnia, and increased oxygen unloading. Whether this may translate into a decrease in the incidence of BPD is unclear. Also, the potential disadvantages from sustained high carbon dioxide levels in premature infants, including hypoxemia, cerebral vasodilation, increase in IVH, and retinopathy of prematurity, cannot be ignored. Clearly, careful evaluation of this approach is necessary. In a large, multicenter, randomized, controlled trial, which included 220 patients with birthweights between 501 and 1,000 g, permissive hypercapnia was not associated with a reduction of BPD. Interestingly, in the hypercapnia group there was significantly less need for ventilatory support at 36 weeks corrected age (1% vs 16% in the control group), whereas there were no differences in other morbidities. Unfortunately, this study was terminated prematurely because of substantial complications (eg, spontaneous intestinal perforation) arising from the concurrent use of steroids.58,59 All forms of mechanical ventilation of the immature lung probably promote some degree of ventilator-induced lung injury. Therefore, techniques that favor spontaneous breathing with early lung recruitment may be required to decrease BPD. Early lung recruitment is crucial and imperative to reduce the deleterious effect of atelectrauma and should probably begin in the delivery room. In recent years, there has been a renewed interest in noninvasive modalities of respiratory support, specifically, CPAP. The use of CPAP, originally introduced in the early
283
MANAGEMENT
OF
in whom complications could be more severe, such as increase in IVH. Several randomized, controlled trials are currently underway, which, it is hoped, will address some of the important currently unresolved issues. The potential benefits of inhaled nitric oxide for the prevention of chronic lung disease is another area of intense research. The currently available evidence is insufficient to recommend the use of inhaled nitric oxide outside randomized, controlled trials in this population, although we have used it in exceptional circumstances, under a compassionate care protocol, with parental informed consent. Summary Despite the tremendous advances in the management of RDS, substantial respiratory morbidity in the form of BPD remains a major problem. Prenatal corticosteroids for lung maturation and postnatal surfactant replacement therapy significantly reduce the incidence, severity, and mortality associated with RDS and are currently considered standard of care. Only natural surfactants are currently available for use in the United States, and there are no significant differences in clinically important outcomes among preparations. The ventilatory management of babies suffering RDS may require further refinement. The new generation of ventilators may allow us to better monitor and control tidal volume delivery to minimize volutrauma while preventing unwanted atelectasis. Based on the currently available clinical data, there is no significant difference in outcomes between conventional and high-frequency ventilation for the management of RDS, although there is considerable center-to-center variation in outcomes. Recent data suggest that HFOV, when used properly, does not seem to increase the incidence of intracranial hemorrhage. Nasal CPAP may reduce the damaging effects of mechanical ventilation on the developing lung. Finally, the general principles of neonatal care and a team approach should be applied to maximize the occurrence of good short-term and long-term outcomes.
REFERENCES 1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517523. 2. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980; 1(8159):5559. 3. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 1993;168(2):508513. 4. Kari MA, Hallman M, Eronen M, Teramo K, Virtanen M, Koivisto M, Ikonen RS. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebocontrolled multicenter study. Pediatrics 1994;93(5):730736.
284
MANAGEMENT
OF
26.
27.
28.
29.
30.
31.
32.
33.
34. 35.
36.
37.
38.
39.
40.
41.
dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group. Pediatrics 1990;86(5):753764. Hallman M, Merritt TA, Jarvenpaa AL, Boynton B, Mannino F, Gluck L, et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial. J Pediatr 1985;106(6):963969. Bose C, Corbet A, Bose G, Garcia-Prats J, Lombardy L, Wold D, et al. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr 1990;117(6):947953. Early versus delayed neonatal administration of a synthetic surfactant: the judgment of OSIRIS. OSIRIS Collaborative Group. Lancet 1992;340(8832):13631369. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med 1994;330(21):14761480. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997;100(1):3138. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1993;123(5):757766. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ, et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996;128(3):396406. Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996;97(1):16. Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996;51(2):226237. Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks gestation. N Engl J Med 1991;324(13):865871. Merritt TA, Hallman M, Berry C, Pohjavuori M, Edwards DK 3rd, Jaaskelainen J, et al. Randomized placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr 1991;118(4 Pt 1):581594. Dunn MS, Shennan AT, Zayack D, Possmayer F. Bovine surfactant replacement therapy in neonates of less than 30 weeks gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 1991;87(3):377386. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, Vilstrup CT. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997;42(e):348355. Rider ED, Jobe AH, Ikegami M, Sun B. Different ventilation strategies alter surfactant responses in preterm rabbits. J Appl Physiol 1992;73(5):20892096. Collaborative European Multicentre Study Group. Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Eur J Pediatr 1991;150(6): 433439. Charon A, Taeusch W, Fitzgibbon C, Smith GB, Treves ST, Phelps DS. Factors associated with surfactant treatment response in infants
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
285
MANAGEMENT
OF
56. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT; Neonatal Ventilation Study Group. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med 2002;347(9):643652. 57. Jobe AH, Kramer BW, Moss TJ, Newnham JP, Ikegami M. Effects of high PCO2 on ventilated preterm lamb lungs. Pediatr Res 2002;2:337A. 58. Carlo WA, Stark AR, Bauer C, Donovan E, Oh W, Papile L-A, et al. Effects of minimal ventilation in a multicenter randomized controlled trial of ventilator support and early corticosteroid therapy in extremely low birthweight infants. Pediatrics 1999;104(3, Suppl):738 739. 59. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001;344(2):95101. 60. Strand M, Ikegami M, Jobe AH. Decreased indicators of lung inflammation with continuous positive aiway pressure (CPAP) versus conventional vetnilation in preterm lambs. Pediatr Res 2002;51:337A. 61. Haberman B, Shankaran S, Stevenson DK, Papile LA, Stark A, Korones S, et al. Does surfactant (S) and immediate extubation to nasal continuous positive airway pressure (CPAP) reduce use of mechanical ventilation? (abstract). Pediatr Res 2002;51:349A. 62. Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Bertel-
63.
64. 65.
66.
67.
68.
Discussion Hansell: At the American Association for Respiratory Care OPEN FORUM last year, Jeanette Asselins group presented some preliminary data on the use of early HFOV, and I believe those data were very encouraging for early use of HFOV.
REFERENCE 1. Asselin JW, Durand DJ, Courtney SE. Early high-frequency oscillatory ventilation (HFOV) vs synchronized intermittent mandatory ventilation (SIMV) for very low birthweight (VLBW) infants (abstract). Respir Care 2001;46(10):1132.
that too many centers were involved and too many different types of devices were used. Three different kinds of high-frequency oscillator were involved, so I think they were comparing apples to oranges.
REFERENCES 1. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birthweight infants. N Engl J Med 2002;347(9):643652. 2. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, Calvert SA; United Kingdom Oscillation Study Group. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 2002; 347(9):633642.
Wiswell: I was on the steering committee for the study you refer to. Its one of the few HFOV trials that have shown benefits. They found less mortality and BPD at 36 weeks post-conception age with HFOV than with conventional ventilation. The study is going to be published in the New England Journal of Medicine.1 In that same issue of that journal will appear whats known as the UKOS trial, from the United Kingdom Oscillation Study Group, which found no differences in outcomes.2 The problem with the latter trial, from my perspective, is
Rodriguez: I appreciate that comment. That reinforces the fact that for each report describing beneficial effects from HFOV, you can find another one that shows no benefits or shows potential complications with HFOV. My personal bias is that there is very substantial center-to-center variability. If Im born in Provo, Utah, Id probably like to be on HFOV. But if Im born somewhere else, maybe not. Maybe clinicians just use what
they are used to and feel more comfortable with. I think HFOV has a role in the management of babies with RDS. At our center we use it as a rescue modality, and maybe thats a little late, since the lungs have already suffered all the damage, and probably thats why we dont see significant benefits. I think there is a subset of patients who may benefit from early institution of HFOV and may never need a conventional ventilator. The Cochrane systematic review1 cannot reconcile that HFOV is better than conventional ventilation. There are some concerns, and Tom Wiswell published a very interesting article in 1996,2 although he used a different strategy, which was termed the low volume strategy at that time, and he raised a very interesting question that has also been raised by other investigators, and thats central nervous system morbiditiesischemic lesions in the form of periventricular leukomalacia and increased incidence of IVH.3 Some of the newer trials, in which an optimal lung volume strategy was used, did not find differences in those outcomes.4 There seemed to be no difference in the incidence of IVH. However, Im still a little reluc
286
MANAGEMENT
OF
tant to suggest that everybody should put kids on HFOV right off the bat.
REFERENCES 1. Henderson-Smart DJ, Bhuta T, Cools F, Offringa M. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4 2002. Oxford: Update Software. Available at http://www. update-software.com/abstracts/titlelist.htm. Accessed Jan 16, 2003 2. Wiswell TE, Graziani LJ, Kornhauser MS, Stanley C, Merton DA, McKee L, Spitzer AR. Effects of hypocarbia on the development of cystic periventricular leukomalacia in premature infants treated with highfrequency jet ventilation. Pediatrics 1996; 98(5):918924. 3. Clark RH, Dykes FD, Bachman TE, Ashurst JT. Intraventricular hemorrhage and highfrequency ventilation: a meta-analysis of prospective clinical trials. Pediatrics 1996; 98(6 Pt 1):10581061. 4. Gerstmann DR, Minton SD, Stoddard RA, Meredith KS, Monaco F, Bertrand JM, et al. The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome. Pediatrics 1996;98(6 Pt 1):10441057.
Rodriguez:
Absolutely.
Myers: John Salyer and his colleagues recently published a report in RESPIRATORY CARE on the use of aerosolized agonists, inhaled corticosteroids, in the RDS population.1 The question is, whats the efficacy of agonists, or how do you determine efficacy in a very small baby, in whom it is difficult to measure lung compliance and resistance?
REFERENCE 1. Ballard J, Lugo RA, Salyer JW. A survey of albuterol administration practices in intubated patients in the neonatal intensive care unit. Respir Care 2002;47(1):3138.
facilitates lung fluid re-absorption, and some of these babies may have some retained lung fluid, which from my point of view is good initially, because it facilitates surfactant spread and surfactant distribution when youre treating them. I like to give surfactant when there is still some lung fluid in place, because the surfactant will be better distributed in the lung. I dont know of any data that strongly suggest that the early use of agonists makes a substantial difference in the management of these babies. Also, there is evidence that suggests that some of the agonists that we use in the neonatal intensive care unit have an inflammatory effect in the lung, at least when used chronically in asthmatic adults.1 Im a little concerned when I see babies who are 3, 4, or 5 days old started on agonists, because that may be promoting more lung inflammation than we know. Before more data are available Im a little reluctant to introduce agonists into the airway of a baby who is in the acute phase of RDS.
REFERENCE 1. Swystun VA, Gordon JR, Davis EB, Zhang X, Cockcroft DW. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol 2000;106(1 Pt 1): 5764.
Donn: Regarding the study by Courtney et al,1 I think we should be careful not to over-interpret the results. It only compared HFOV to synchronized intermittent mandatory ventilation, and that might not be the best
Rodriguez: Thats a very good point. Actually, Im a little concerned about the early use of agonists in babies with RDS. Im not sure whether there is a role for agonists early on in the course of RDS. stimulation
287